Skip to main content
SpringerLink
Log in

Proteomic Analysis of Blood and Pancreatic Juice

  • Chapter
  • First Online:
Drug Discovery in Pancreatic Cancer

  • 694 Accesses

Abstract

The proteome is the complete set of proteins present in a defined cellular or extracellular compartment. A number of studies have been undertaken to characterise the protein profiles of plasma/serum and pancreatic juice, and protein differences between samples from cancer patients and benign disease controls or healthy individuals have been defined. More recently, advances in liquid chromatography-mass spectrometry (LC-MS) instrumentation, as well as developments in quantitative proteomic approaches, and analysis of post-translational modifications have enabled interrogation of cancer pathways and the effects of drugs on those pathways. For targeted drugs to be used effectively, biomarkers that provide information regarding drug activity, toxicity or patient response are essential. Such biomarkers are particularly useful if they can be detected in samples that are readily accessible, such as plasma/serum. The application of proteomic techniques affords opportunities for discovering and evaluating biomarkers that aid the process of drug development. In this chapter, some of the recent advances in proteomic techniques that enable the detection and quantification of proteins in blood and pancreatic juice will be reviewed. Particular emphasis will be placed on the significance of these advances for novel treatments of pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Anderson NG, Ahmad T, Chan K et al (2001) ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94:774–782

    Article  CAS  PubMed  Google Scholar 

  • Aspinall-O’Dea M, Costello E (2007) The pancreatic cancer proteome – recent advances and future promise. Proteomics Clin Appl 1:1066–1079

    Article  Google Scholar 

  • Barker AJ, Gibson KH, Grundy W et al (2001) Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11:1911–1914

    Article  CAS  PubMed  Google Scholar 

  • Barton CM, Hall PA, Hughes CM et al (1991) Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 163:111–116

    Article  CAS  PubMed  Google Scholar 

  • Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95

    Article  CAS  PubMed  Google Scholar 

  • Bielenberg DR, Klagsbrun M (2007) Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev 26:421–431

    Article  CAS  PubMed  Google Scholar 

  • Blaszkowsky LS, Ryan DP, Earle C et al (2007) A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer. J Clin Oncol (Meeting Abstracts) 25:15080

    Google Scholar 

  • Bloomston M, Zhou JX, Rosemurgy AS et al (2006) Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res 66:2592–2599

    Article  CAS  PubMed  Google Scholar 

  • Camp ER, Yang A, Liu W et al (2006) Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin Cancer Res 12:2628–2633

    Article  CAS  PubMed  Google Scholar 

  • Cappuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655

    Article  CAS  PubMed  Google Scholar 

  • Chen R, Pan S, Yi EC et al (2006) Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 6:3871–3879

    Article  CAS  PubMed  Google Scholar 

  • Chen R, Pan S, Aebersold R et al (2007a) Proteomics studies of pancreatic cancer. Proteomics Clin Appl 1:1582–1591

    Article  CAS  Google Scholar 

  • Chen R, Pan S, Cooke K et al (2007b) Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 34:70–79

    Article  Google Scholar 

  • Ciardiello F, Caputo R, Bianco R et al (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459–1465

    CAS  PubMed  Google Scholar 

  • Denduluri N, Yang SX, Berman AW et al (2008) Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther 7:15–20

    Article  CAS  PubMed  Google Scholar 

  • Deng R, Lu Z, Chen Y et al (2007) Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas 34:310–317

    Article  CAS  PubMed  Google Scholar 

  • Dragovich T, Burris H III, Loehrer P et al (2008) Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 31:157–162

    Article  CAS  PubMed  Google Scholar 

  • Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380

    Article  CAS  PubMed  Google Scholar 

  • Ehmann M, Felix K, Hartmann D et al (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34:205–214

    Article  CAS  PubMed  Google Scholar 

  • Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591

    Article  CAS  PubMed  Google Scholar 

  • Faca VM, Song KS, Wang H et al (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5:e123

    Article  PubMed  Google Scholar 

  • Fountzilas G, Murray S, Xiros N et al (2007) Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer. A phase II trial. J Clin Oncol (Meeting Abstracts) 25:15016

    Google Scholar 

  • Friess H, Wang L, Zhu Z et al (1999) Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Ann Surg 230:767–774; discussion 774–765

    Google Scholar 

  • Ghaneh P, Costello E, Neoptolemos JP (2007) Biology and management of pancreatic cancer. Gut 56:1134–1152

    Article  CAS  PubMed  Google Scholar 

  • Gorg A, Obermaier C, Boguth G et al (2000) The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21:1037–1053

    Article  CAS  PubMed  Google Scholar 

  • Grantzdorffer I, Carl-McGrath S, Ebert MP et al (2008) Proteomics of pancreatic cancer. Pancreas 36:329–336

    Article  PubMed  Google Scholar 

  • Gronborg M, Bunkenborg J, Kristiansen TZ et al (2004) Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 3:1042–1055

    Article  CAS  PubMed  Google Scholar 

  • Harsha HC, Jimeno A, Molina H et al (2008) Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res 7:4651–4658

    Article  CAS  PubMed  Google Scholar 

  • Hecht JR, Trarbach T, Jaeger E et al (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol (Meeting Abstracts) 23:LBA3

    Google Scholar 

  • Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027

    Article  CAS  PubMed  Google Scholar 

  • Honda K, Hayashida Y, Umaki T et al (2005) Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 65:10613–10622

    Article  CAS  PubMed  Google Scholar 

  • Kimura K, Sawada T, Komatsu M et al (2006) Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 12:4925–4932

    Article  CAS  PubMed  Google Scholar 

  • Kindler HL, Friberg G, Singh DA et al (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033–8040

    Article  CAS  PubMed  Google Scholar 

  • Klagsbrun M, Takashima S, Mamluk R (2002) The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 515:33–48

    CAS  PubMed  Google Scholar 

  • Kobayashi A, Yamaguchi T, Ishihara T et al (2005) Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival. Pancreas 31:74–78

    Article  CAS  PubMed  Google Scholar 

  • Koehne C, Bajetta E, Lin E et al (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol (Meeting Abstracts) 24:3508

    Google Scholar 

  • Koopmann J, Zhang Z, White N et al (2004) Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10:860–868

    Article  CAS  PubMed  Google Scholar 

  • Korc M, Chandrasekar B, Yamanaka Y et al (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90:1352–1360

    Article  CAS  PubMed  Google Scholar 

  • Kruse U, Bantscheff M, Drewes G et al (2008) Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. Mol Cell Proteomics 7:1887–1901

    Article  CAS  PubMed  Google Scholar 

  • Kummar S, Kinders R, Rubinstein L et al (2007) Compressing drug development timelines in oncology using phase ‘0’ trials. Nat Rev Cancer 7:131–139

    Article  CAS  PubMed  Google Scholar 

  • Kuo T, Cabebe EC, Koong A et al (2008) An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (Meeting Abstracts) 26:15571

    Google Scholar 

  • Lange V, Picotti P, Domon B et al (2008) Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 4:222

    Article  PubMed  Google Scholar 

  • Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281

    Article  PubMed  Google Scholar 

  • Lin Y, Goedegebuure PS, Tan MCB et al (2006) Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J Proteome Res 5:2169–2176

    Article  CAS  PubMed  Google Scholar 

  • Linardou H, Dahabreh IJ, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972

    Article  CAS  PubMed  Google Scholar 

  • Loperfido S, Angelini G, Benedetti G et al (1998) Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 48:1–10

    Article  CAS  PubMed  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  CAS  PubMed  Google Scholar 

  • Macek B, Mann M, Olsen JV (2008) Global and site-specific quantitative phosphoproteomics: principles and applications. Annu Rev Pharmacol Toxicol 49:199–221

    Article  Google Scholar 

  • Maisey NR, Norman AR, Hill A et al (2005) CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93:740–743

    Article  CAS  PubMed  Google Scholar 

  • Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107:1207–1218

    Article  CAS  PubMed  Google Scholar 

  • Masago K, Fujita S, Hatachi Y et al (2008) Clinical significance of pretreatment serum amphiregulin and transforming growth factor-α, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci 99:2295–2301

    Article  CAS  PubMed  Google Scholar 

  • Merchant M, Weinberger SR (2000) Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21:1164–1177

    Article  CAS  PubMed  Google Scholar 

  • Middleton G, Ghaneh P, Costello E et al (2008) New treatment options for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol 2:673–696

    Article  CAS  PubMed  Google Scholar 

  • Miribel L, Gianazza E, Arnaud P (1988) The use of dye-ligand affinity chromatography for the purification of non-enzymatic human plasma proteins. J Biochem Biophy Methods 16:1–15

    Article  CAS  Google Scholar 

  • Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

    Article  CAS  PubMed  Google Scholar 

  • Morabito A, De Maio E, Di Maio M et al (2006) Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11:753–764

    Article  CAS  PubMed  Google Scholar 

  • Novotny J, Petruzelka L, Vedralova J et al (2001) Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma 48:188–191

    CAS  PubMed  Google Scholar 

  • O’Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007–4021

    PubMed  Google Scholar 

  • Okada N, Ohshio G, Yamaki K et al (1995) Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival. Oncology 52:392–396

    Article  CAS  PubMed  Google Scholar 

  • Ong SE, Mann M (2005) Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 1:252–262

    Article  CAS  PubMed  Google Scholar 

  • Ong SE, Blagoev B, Kratchmarova I et al (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1:376–386

    Article  CAS  PubMed  Google Scholar 

  • Pratesi G, Petrangolini G, Tortoreto M et al (2008) Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. J Immunother 31:537–544

    Article  CAS  PubMed  Google Scholar 

  • Reckamp KL, Krysan K, Morrow JD et al (2006) A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12:3381–3388

    Article  CAS  PubMed  Google Scholar 

  • Reckamp KL, Gardner BK, Figlin RA et al (2008) Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol 3:117–124

    Article  PubMed  Google Scholar 

  • Ross JS, Fletcher JA, Bloom KJ et al (2004) Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 3:379–398

    Article  CAS  PubMed  Google Scholar 

  • Rosty C, Christa L, Kuzdzal S et al (2002) Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 62:1868–1875

    CAS  PubMed  Google Scholar 

  • Saeki H, Yanoma S, Takemiya S et al (2007) Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. Oncol Rep 18:433–439

    CAS  PubMed  Google Scholar 

  • Saxby AJ, Nielsen A, Scarlett CJ et al (2005) Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 29:1125–1134

    Article  PubMed  Google Scholar 

  • Schneider MR, Wolf E (2008) The epidermal growth factor receptor ligands at a glance. J Cell Physiol

    Google Scholar 

  • Schreiber TB, Mausbacher N, Breitkopf SB et al (2008) Quantitative phosphoproteomics—an emerging key technology in signal-transduction research. Proteomics 8:4416–4432

    Article  CAS  PubMed  Google Scholar 

  • Sennels L, Salek M, Lomas L et al (2007) Proteomic analysis of human blood serum using peptide library beads. J Proteome Res 6:4055–4062

    Article  CAS  PubMed  Google Scholar 

  • Shadforth I, Dunkley T, Lilley K et al (2005) i-Tracker: for quantitative proteomics using iTRAQTM. BMC Genomics 6:145

    Article  PubMed  Google Scholar 

  • Shiio Y, Aebersold R (2006) Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. Nat Protoc 1:139–145

    Article  CAS  PubMed  Google Scholar 

  • Sjobring U, Bjorck L, Kastern W (1991) Streptococcal protein G. Gene structure and protein binding properties. J Biol Chem 266:399–405

    CAS  PubMed  Google Scholar 

  • Smith RA, Bosonnet L, Ghaneh P et al (2008) The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 143:658–666

    Article  PubMed  Google Scholar 

  • Soker S, Takashima S, Miao HQ et al (1998) Neuropilin-1 Is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735–745

    Article  CAS  PubMed  Google Scholar 

  • Soker S, Miao H-Q, Nomi M et al (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 85:357–368

    Article  CAS  PubMed  Google Scholar 

  • Suissa A, Yassin K, Lavy A et al (2005) Outcome and early complications of ERCP: a prospective single center study. Hepatogastroenterology 52:352–355

    CAS  PubMed  Google Scholar 

  • Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615

    Article  PubMed  Google Scholar 

  • Taguchi F, Solomon B, Gregorc V et al (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99:838–846

    Article  CAS  PubMed  Google Scholar 

  • Thompson ST, Cass KH, Stellwagen E (1975) Blue dextran-sepharose: an affinity column for the dinucleotide fold in proteins. Proceedings of the National Academy of Sciences 72:669–672

    Google Scholar 

  • Tian M, Cui YZ, Song GH et al (2008) Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8:241

    Article  PubMed  Google Scholar 

  • Unlu M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18:2071–2077

    Article  CAS  PubMed  Google Scholar 

  • Vandervoort J, Soetikno RM, Tham TC et al (2002) Risk factors for complications after performance of ERCP. Gastrointest Endosc 56:652–656

    Article  PubMed  Google Scholar 

  • Vervenne W, Bennouna J, Humblet Y et al (2008) A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol (Meeting Abstracts) 26:4507

    Google Scholar 

  • Wang YY, Cheng P, Chan DW (2003) A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 3:243–248

    Article  CAS  PubMed  Google Scholar 

  • Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389–4400

    Article  CAS  PubMed  Google Scholar 

  • Wong HH, Lemoine NR (2008) Biological approaches to therapy of pancreatic cancer. Pancreatology 8:431–461

    Article  PubMed  Google Scholar 

  • Wood JM, Bold G, Buchdunger E et al (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189

    CAS  PubMed  Google Scholar 

  • Wu WW, Wang G, Baek SJ et al (2006) Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D Gel- or LC-MALDI TOF/TOF. J Proteome Res 5:651–658

    Article  CAS  PubMed  Google Scholar 

  • Yamanaka Y, Friess H, Kobrin MS et al (1993a) Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565–569

    CAS  Google Scholar 

  • Yamanaka Y, Friess H, Kobrin MS et al (1993b) Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 24:1127–1134

    Article  CAS  Google Scholar 

  • Yan L, Tonack S, Smith R et al (2009) Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res 8:142–148

    Article  CAS  PubMed  Google Scholar 

  • Zolla L (2008) Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins. Drug Discov Today 13:1042–1051

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgery and Oncology, Royal Liverpool University Hospital, University of Liverpool, Daulby Street, Liverpool, Merseyside, UK

    Eithne Costello

Authors
  1. Mark Aspinall-O’Dea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Neoptolemos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eithne Costello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eithne Costello .

Editor information

Editors and Affiliations

  1. Institute, Translational Genomics Research, 445 N. Fifth Street, Phoenix, 85004, U.S.A.

    Haiyong Han

  2. Feinberg School of Medicine, Northwestern University, Chicago, 60611, U.S.A.

    Paul Grippo

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Aspinall-O’Dea, M., Neoptolemos, J., Costello, E. (2010). Proteomic Analysis of Blood and Pancreatic Juice. In: Han, H., Grippo, P. (eds) Drug Discovery in Pancreatic Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1160-5_12

Download citation

Publish with us

Policies and ethics

Search

Navigation